Hydroxychloroquine could be a game changer
Hydroxychloroquine could be a game-changer
US President Donald Trump has called Hydroxychloroquine a potential “game-changer” for treating the disease caused by the novel coronavirus SARS-COV-2. Hydroxychloroquine is a derivative of chloroquine, with lesser side-effects.
One of a US-based Nonprofit organization, “Patient-Centered Outcomes Research Institute” (PCORI), has approved around us $50 million funding to arrange a clinical trial for testing if malaria drug hydroxychloroquine (HCQ) can prevent COVID-19 infections in healthcare workers.
President has announced 29 million doses of hydroxychloroquine will be stockpiled as well as the immediate distribution of the drug as the country grapples with the COVID-19 pandemic.
Till now there’s no scientific evidence that hydroxychloroquine can treat the infection from the novel Coronavirus, or prevents by getting infected and it hasn’t been approved by the Food and Drug Administration in the U.S. to treat COVID-19.
Trump said at a White House news conference. “we've bought a tremendous amount of is the hydroxychloroquine which is a great malaria drug. it's worked unbelievably it's as powerful drug on malaria and there are signs that it works on this, some very strong signs, I've seen things I sort of like. What do I know, I’m not a doctor, But I have common sense.” Touting the drug’s promise despite an absence of scientific scrutiny. Saying he was “trying to save lives,” the president asked, “what really do we have to lose?”
At a press conference on Saturday, Trump said he spoke to Indian Prime Minister Narendra Modi and appealed for the release of shipments U.S. has already ordered. India is giving his request “serious consideration,”
India banned all exports of hydroxychloroquine, a malaria drug that President Donald Trump has repeatedly touted as a “game-changer” in the fight against COVID-19.
Indian Council of Medical Research (ICMR) has also recommended the use of the drug for those involved in the care of ‘suspected or confirmed cases of the COVID-19 and for asymptomatic household contacts of laboratory confirmed patients, apart from healthcare workers who are involved in the treatment of COVID-19.’
The Centre has placed the order after ICMR recommended hydroxychloroquine as a preventive medication for COVID-19 high-risk group.
India is a leading country across the world in the manufacturing of hydroxychloroquine (HCQ) with Ipca laboratories, Zydus Cadila and Wellona Pharma as top pharma companies. the country’s production capacity is 20 crore tablets every month.
Indian Govt places order for 10 crore hydroxychloroquine tablets with Ipca labs and Zydus Cadila. the country’s production capacity is 20 crore tablets every month.
What is hydroxychloroquine and how does it works?
Hydroxychloroquine is one of several antimalarial drugs that have anti-inflammatory effects useful in other diseases like Rheumatoid arthritis, Autoimmune diseases.
Hydroxychloroquine is particularly effective for systemic lupus erythematosus (SLE) and discoid lupus erythematosus (DLE). By reducing inflammation,
hydroxychloroquine can decrease pain, swelling and stiffness of joints, and
improve or clear some rashes.
What are the possible side effects of hydroxychloroquine?
Side effects are uncommon; however, a few people may develop one of the following: rash, indigestion, diarrhea, headache, blurred vision, cramps or muscle weakness, darkening of the skin, or bleaching of the hair.
Hydroxychloroquine can aggravate pre-existing psoriasis.
Before starting on hydroxychloroquine your doctor may wish to carry out a blood test to check that your liver and kidneys are working normally. It should not be necessary to carry out regular blood tests.